Patent · US Active

N-acetyl glucosamine as a biomarker of MS disease course

US10495646B2 · kind B2 · utility

0Cited by

0References

4Claims

0Family size

Assignees

The Regents of the University of California · US
CHARITÉ—UNIVERSITÄTSMEDIZIN BERLIN · DE
Mt. Sinai Hospital · CA

Inventors

Michael Demetriou · Irvine, US
Alexander Brandt · Wesel, DE
Friedmann Paul · Berlin, DE
James Dennis · Mississauga, CA

Key dates

Filing date	Jan 29, 2016
Grant date	Dec 3, 2019
Priority date	—
Expiry date	Apr 8, 2036

Classification

Technology area (CPC G)Physics
CPC primaryG01N2800/52
WIPO fieldMeasurement
WIPO sectorInstruments

Abstract

The invention provides the art with a powerful diagnostic method of distinguishing relapse-remitting MS subjects from progressive MS subjects, based on the measurement of serum concentrations of N-acetylglucosamine (GlcNAc,), for the first time enabling rapid diagnosis of the progressive form of MS. GlcNAc serum concentration can also be used to assess neurodegenerative status and MS progression in subjects suffering from MS or other neurological conditions. The methods of the invention also allow for the identification of new therapeutics for MS and other neurological conditions and also enables the personalized efficacy assessment of a potential therapy for an MS subject.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.